Document is current
Any future updates will be listed below
-
Authors
Boiarsky, Rebecca https://orcid.org/0000-0002-8817-8086
Singh, Nalini M.
Buendia, Alejandro
Amini, Ava P. https://orcid.org/0000-0002-8601-6040
Getz, Gad https://orcid.org/0000-0002-0936-0753
Sontag, David
-
Funding
Funding for this research was provided by:
The Mark Foundation for Cancer Research, Grant Number: 19-010-ASP
Google
- License Information
-
More Information
Article History
Received: 19 September 2023
Accepted: 5 November 2024
First Online: 12 December 2024
Competing interests
: G.G. receives research funds from IBM, Pharmacyclics/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras and Google. G.G. is a founder, consultant, and has privately held equity in Scorpion Therapeutics; G.G. is a founder of and holds privately held equity in PreDICTA Biosciences. G.G. is also an inventor on patent applications filed by the Broad Institute related to MSMuTect and MSMutSig (WO 2019/083594); POLYSOLVER (US-2016-0298185); SignatureAnalyzer-GPU (US-2021-0358574); MSEye/MSIDetect (WO 2022/098997 and WO 2022/099004); and MinimuMM-seq (WO 2023/102513); D.S. is president and CEO of Layer Health, has privately held equity in Curai and ASAPP, and receives research funds from Takeda and IBM. N.S. was funded by a PhD fellowship from Google at the time of this work. The other authors declare no competing interests.
